Darlene Soave Joins Cell Source s Board of Directors
News provided by
Share this article
Share this article
NEW YORK, April 1, 2021 /PRNewswire/ Cell Source, Inc. (OTC: CLCS) ( Cell Source or the Company ), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company s Board of Directors, effective March 25, 2021. Veto Cells, in different mouse models, have shown that they have the potential to safely facilitate mismatched donor stem cell (e.g. bone marrow) transplants and organ transplants. In addition, in preclinical trials, Veto Cells have shown that they can durably treat malignant and non-malignant blood diseases through active immune response management.
/PRNewswire/ Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely.
Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.